The Latest Covid Vaccine Results, Deciphered

An experimental Covid-19 vaccine from Pfizer and German drug developer BioNTech (BNT) seems to be working very well, according to early trial data. The announcement, made on Monday, has enormous implications. If we end up with a few vaccines that are as effective as this one appears to be, then very widespread vaccination could be a steamroller for public health, slowly crushing the pandemic.

The details, though, are complicated, and the press coverage to this point has often been off target. Some stories underplay the good news with spurious caveats, such as the claim that the numbers are drawn from “a very small number” of cases. Others have overplayed it—wrongly claiming, for example, that the vaccine has been shown to be more than 90 percent effective at preventing infections, or that it has “displayed no side effects.” Here’s what we do know: Pfizer and BNT have just hiked up the bar for Covid-19 vaccines; and while it’s not yet clear exactly how high that bar now sits, there’s every reason to think it’s pretty high.

First, was the number of infections really that small? Long before any results came in, the protocol for this trial calculated what sort of data—including how many people ended up getting sick—would need to be tallied in order to know that the vaccine had cleared the minimum requirement of 50-percent effectiveness set by the Food and Drug Administration. (A vaccine that prevents about half of illnesses would be more like a flu shot than a measles immunization—not enough to squash the pandemic on its own, but still much better than nothing.) It’s tricky, because there was no telling where the virus might surge in the first few months of the trial. To get an answer fast, you would need to have a lot of people in both the vaccinated and control groups who were sitting in the virus’ possible path—far more people than you would need if you were running your trial on, say, a giant cruise ship about to have an out-of-control outbreak. That’s why it was necessary to have tens of thousands of wonderful people as volunteers, but the required number of actual “events”—in this case, volunteers getting symptomatic Covid-19—would be small, if the vaccine were to end up making a really big difference.

An independent data monitoring group was scheduled to look at the data at several points along the way, to check whether it was having a dramatically good or bad impact. That’s a process with a lot of planning and safeguards. BNT and Pfizer originally planned to have this group check in with four interim analyses, once certain numbers of events had been recorded. The companies were criticized, though, for allowing themselves too many opportunities to stop the trial early, and for planning to have the first analysis when there were just 32 events. “Take the time, the extra weeks,” one expert told The New York Times. “No shortcuts. Nobody will regret it.”

Monday’s press release reports that there had been negotiations with the FDA to drop the earliest analysis, but by the time the new protocol was signed off, there were already enough events to skip ahead to what would have been the third analysis. Now, with the virus surging in the US, the full number of events required for this trial—a total of 164 volunteers getting sick—may even be reached in the coming weeks. For the moment, the companies are only reporting on the first 94 events.

bonuses
breaking news
browse around here
browse around these guys
browse around this site
browse around this web-site
browse around this website
browse this site
check
check here
check it out
check out the post right here
check out this site
check out your url
check over here
check these guys out
check this link right here now
check this out
check this site out
click
click for info
click for more
click for more info
click for source
click here
click here for info
click here for more
click here for more info
click here now
click here to find out more
click here to investigate
click here to read
click here!
click here.
click now
click over here
click over here now
click this
click this link
click this link here now
click this link now
click this over here now
click this site
click to find out more
click to investigate
click to read
clicking here
company website
consultant
content
continue
continue reading
continue reading this
continue reading this..
continued
conversational tone
cool training
Get the facts
Related Site
Recommended Reading
Recommended Site
describes it
description
dig this
directory
discover here
discover more
discover more here
discover this
discover this info here
do you agree
enquiry
experienced
explanation
extra resources
find
find more
find more info
find more information

Read all of our coronavirus coverage here.

So there really isn’t a reason to be concerned about the number of events included in this analysis. What about the results—have BNT and Pfizer really shown that the vaccine is “more than 90 percent effective at preventing infections”? No. For one thing, we have no information on how many people in the study were infected with the virus—only a number who actually ended up getting sick and diagnosed with Covid-19. The “90 percent” figure is also up in the air, for the time being. Because there’s more uncertainty in the smaller numbers that emerge early in the trial, the hurdle for declaring success must be set higher than 50 percent. The companies had calculated ahead of time that if they found the vaccine to be 62.7 percent effective at around this point, they could be confident the vaccine would turn out to be at least 50 percent effective overall. On the other hand, if that number were lower than 38.6 percent, it would mean the trial was never going to be able to clamber over the bar. When the data-monitoring board made its examination, the effectiveness rate was more than 90 percent for people who had definitely been Covid-free before the trial started. (Wow.) That rate could drop when the next 70 events join this unlucky group, but it should still be well clear of the FDA’s minimum requirement. On the other hand, it could end up considerably higher than 90 percent, too.

There’s still a lot to be determined. Note that they’ve only told us the result for people who were definitely Covid-free when the trial started. When a vaccine is eventually rolled out to the public, some people who get it will already have had Covid-19 without knowing it. The same is true for trial participants. We don’t yet know the effectiveness rate for everyone in the trial, and it’s not clear how much data is missing because volunteers didn’t check back in with the people running the study, for example. Nor do we know whether the vaccine prevents asymptomatic infections or protects against severe illness among those who do get sick. The latter question is very important, because a vaccine that only prevents mild illness might help reduce the spread of the virus, but it won’t save as many lives, and as quickly. We also need to be sure being vaccinated doesn’t increase the risk of severe illness, which is theoretically possible.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *